DOVER, DE
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)PROSTATE CANCER RESEARCH INC, founded in 2020, is a micro nonprofit in the Medical Research sector that reported $23K in total revenue in fiscal year 2023. Expenses of $421K exceeded revenue, resulting in a 1755% operating deficit.
THE ORGANIZATION'S HAS 6 CORE GOALS TO GUIDE THEIR DECISION MAKING. THE FIRST GOAL IS TO BECOME THE GOLD STANDARD FOR PROSTATE CANCER RESEARCH. GOAL 2 IS TO STRENGTHEN THEIR CREDIBILITY AND REPUTATION AMONG THE RESEARCH COMMUNITY. GOAL 3 IS TO FORM PARTNERSHIPS AND BUILD BRIDGES BETWEEN THE SCIENTIFIC COMMUNITY, GOVERNMENT, THE PHARMACEUTICAL INDUSTRY & THOSE AFFECTED BY PROSTATE CANCER. GOAL 4 IS TO ASSEMBLE EXPERTS ON ALL ASPECTS OF RUNNING A SUCCESSFUL AND ROBUST RESEARCH CHARITY. GOAL 5 IS TO FOSTER A CULTURE OF CONTINUOUS LEARNING, AND BUILD A SHARED SENSE OF PURPOSE TO ACHIEVE THEIR GOALS. GOAL 6 IS TO CREATE SUSTAINABLE GROWTH BY TAKING A DUAL APPROACH OF BIDDING FOR LARGER GRANTS, WHILE ALSO STRATEGICALLY INVESTING FUNDS TO BUILD FLEXIBLE FUNDING.
PRC WORKS TO PROVIDE RESEARCH ON PROSTATE CANCER FOCUSING ON TWO CORE THEMES. 1 - HOW TO IMPROVE THE CLASSIFICATIONS OF ADVANCED PROSTATE CANCER, AND THEIR ABILITY TO PREDICT WHICH TREATMENTS WILL...
PRC WORKS TO PROVIDE RESEARCH ON PROSTATE CANCER FOCUSING ON TWO CORE THEMES. 1 - HOW TO IMPROVE THE CLASSIFICATIONS OF ADVANCED PROSTATE CANCER, AND THEIR ABILITY TO PREDICT WHICH TREATMENTS WILL WORK BEST FOR INDIVIDUAL PATIENTS BASED ON THEIR PARTICULAR PROSTATE CANCER SUBTYPE. 2 DISCOVERING NEW TREATMENTS FOR ADVANCED PROSTATE CANCER BY INVESTIGATING HOW TO CONTAIN CANCEROUS CELLS WITHIN THE PROSTATE AND PREVENT IT FROM BECOMING ADVANCED, AND FINDING THERAPIES FOR WHEN THE DISEASE HAS BECOME ADVANCED.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $22,687 | N/A | N/A |
| Expenses | $420,739 | $293,728 | +0.4% |
| Net Income | $-398,052 | $-293,728 | +0.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MICHELLE MCGUINNESS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ADAM SCHAYOWITZ | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CHRISTOPHER SHEPARD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| SUMAN SHIRODKAR | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CHRISTINA RENNER-THOMAS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CATHERINE C TURKEL | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| RICHARD COLLIER | PRESIDENT | 5.00 |
Officer
|
$0 | $0 | $0 |
| JOHN WETHERINGTON | TREASURER | 5.00 |
Officer
|
$0 | $0 | $0 |
| OLIVER KEMP | SECRETARY | 5.00 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2023 | $22,687 | $420,739 | $30,551 | $-398,052 |
| 2022 | No data | $293,728 | $29,232 | No data |
| 2021 | $33,109 | $179,095 | $17,070 | $-145,986 |
Compare PROSTATE CANCER RESEARCH INC with other nonprofits in Delaware and across the country.